Market Overview:
The south korea cancer biomarkers market is experiencing rapid growth, driven by the increasing prevalence of different types of cancer across the country, technological advancements in genomics and proteomics, and strong government support for precision diagnostics and oncology research. According to IMARC Group's latest research publication, "South Korea Cancer Biomarkers Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034," the South Korea cancer biomarkers market size reached USD 596.52 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,532.13 Million by 2034, exhibiting a growth rate (CAGR) of 11.05% during 2026-2034.
This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.
Our report includes:
Market Dynamics
Market Trends and Market Outlook
Competitive Analysis
Industry Segmentation
Strategic Recommendations
Growth Factors in the South Korea Cancer Biomarkers Market
Rising Cancer Prevalence Fueling Demand for Early Detection Solutions
The escalating burden of cancer in South Korea is one of the most significant forces driving demand for biomarker-based diagnostics. The country recorded approximately 292,221 newly diagnosed cancer cases and 83,770 cancer-related deaths in a single year, with thyroid, colorectal, lung, breast, and stomach cancers collectively accounting for 55.7% of the total cancer burden. This concentration of cases across a defined set of cancer types creates a compelling case for biomarker-led early detection, as identifying malignancies at early stages results in substantially better treatment outcomes and meaningfully lower cost burdens per patient. Healthcare providers across both public and private institutions are responding by integrating biomarker screening into routine health check-ups and cancer surveillance programmes. Growing patient awareness of preventive screening is further supporting this integration, positioning the south korea cancer biomarkers market as a critical pillar of the nation's broader cancer management strategy.
Advancements in Genomics, Proteomics, and High-Throughput Technologies
Rapid improvements in molecular profiling technologies are expanding the reliability, scope, and affordability of cancer biomarker testing, directly contributing to wider clinical adoption. Omic technologies, including genomics, proteomics, and metabolomics, now enable clinicians to interrogate tumour behaviour at the molecular level and design personalised treatment pathways with greater precision. Immunoassays remain the most widely deployed platform across hospitals and diagnostic laboratories owing to their cost-effectiveness and compatibility with existing laboratory infrastructure, while imaging technologies are bridging molecular diagnostics with established radiology workflows. Genetic biomarkers are increasingly used for mutation-specific targeting in lung and breast cancers, while protein biomarkers support non-invasive blood-based monitoring across multiple cancer types. These technological advances have collectively lifted biomarker testing out of specialist research settings and into routine clinical practice, significantly broadening the addressable base of the south korea cancer biomarkers market.
Government Initiatives and Institutional Investment in Oncology Research
Strong and consistent government support is playing a decisive role in accelerating the development and commercialisation of cancer biomarker solutions. The Ministry of Health and Welfare and the Ministry of Science and ICT are both actively channelling resources into biomedical innovation as part of South Korea's national strategy to emerge as a global leader in biotechnology. The Osong Medical Innovation Foundation, a dedicated bio-cluster, provides infrastructure funding and incubation support for startups and research institutions focused on cancer biomarker development. Regulatory reforms and streamlined clinical trial approval processes are shortening timelines from scientific discovery to market deployment. In November 2024, South Korea's National Institute of Food and Drug Safety Evaluation formalised a Memorandum of Understanding with the U.S. National Cancer Institute to foster joint cancer research initiatives, professional exchanges, and training programmes focused on prevention, diagnosis, and treatment, reinforcing South Korea's position in the global oncology research ecosystem.
Download a sample PDF of this report:
https://www.imarcgroup.com/south-korea-cancer-biomarkers-market/requestsample
Key Trends in the South Korea Cancer Biomarkers Market
AI Integration Transforming Biomarker Discovery and Analysis
Artificial intelligence is increasingly embedded in cancer biomarker research workflows, accelerating the pace and precision of discovery. In March 2025, South Korea-based Lunit announced a strategic partnership with the U.S. National Cancer Institute to advance AI-powered biomarker research, applying its SCOPE IO and SCOPE Universal IHC tools to whole-slide pathology images from NCI's clinical trials. The collaboration aims to deepen understanding of tumour microenvironments and immune phenotyping, supporting the development of more effective personalised immunotherapy strategies. AI-driven platforms are now enabling clinicians and researchers to analyse complex molecular datasets with greater speed and accuracy, improving the identification of actionable biomarkers and reducing the manual burden of interpretation. This convergence of artificial intelligence with oncology diagnostics is emerging as a defining characteristic of the next phase of south korea cancer biomarkers market growth.
Population-Scale Proteomics Opening New Frontiers in Early Detection
Large-scale proteomics initiatives are expanding the discovery pipeline for novel cancer biomarkers, particularly for population segments historically underserved by conventional screening protocols. In June 2025, Seer, Inc. and Korea University launched a landmark three-year population-scale proteomics study under South Korea's K-Health MIRAE programme, analysing 20,000 plasma samples using the Proteograph ONE assay and SP200 automation platform combined with AI-driven mass spectrometry. The study specifically targets young adults in their 20s and 30s, a demographic where rising cancer incidence has not been adequately addressed by existing screening frameworks. By generating high-resolution proteomic profiles at population scale, this initiative aims to identify blood-based biomarkers capable of detecting cancer at the earliest possible stages, setting a new benchmark for early detection sensitivity and scalability within the south korea cancer biomarkers market.
Expanding Application of Biomarkers Across the Full Cancer Care Continuum
The utility of cancer biomarkers in South Korea is no longer confined to diagnostics. Prognostic applications are enabling clinicians to predict disease trajectory and calibrate treatment intensity on an individualised basis. Risk assessment is extending biomarker deployment to pre-symptomatic populations, supporting preventive intervention for genetically predisposed individuals before any malignancy is present. Drug discovery and development represents an especially dynamic frontier, with companion diagnostics using biomarkers to identify patients most likely to respond to specific therapies, improving clinical trial efficiency and increasing the commercial viability of targeted oncology drugs. This multi-application expansion is broadening the revenue base of the south korea cancer biomarkers market beyond hospital diagnostics and into pharmaceutical development, academic research, and population health management.
Leading Companies Operating in the South Korea Cancer Biomarkers Industry:
Lunit Inc.
Seer, Inc.
Korea University (research partnerships)
National Institute of Food and Drug Safety Evaluation (NIFDS)
Osong Medical Innovation Foundation
South Korea Cancer Biomarkers Market Report Segmentation:
By Profiling Technology:
Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics
The market is segmented by profiling technology into omic technologies, imaging technologies, immunoassays, and cytogenetics.
By Biomolecule:
Genetic Biomarkers
Protein Biomarkers
Glyco-Biomarkers
The south korea cancer biomarkers market is categorised by biomolecule into genetic biomarkers, protein biomarkers, and glyco-biomarkers.
By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
The market is segmented by cancer type into breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others.
By Application:
Diagnostics
Prognostics
Risk Assessment
Drug Discovery and Development
Others
The market is categorised by application into diagnostics, prognostics, risk assessment, drug discovery and development, and others.
By End User:
Hospitals
Academic and Research Institutions
Ambulatory Surgical Centers
Diagnostic Laboratories
Others
The market is segmented by end user into hospitals, academic and research institutions, ambulatory surgical centers, diagnostic laboratories, and others.
Regional Insights:
Seoul Capital Area
Yeongnam (Southeastern Region)
Honam (Southwestern Region)
Hoseo (Central Region)
Others
The regional breakdown includes the Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and others, with the Seoul Capital Area holding the largest market share owing to its dense concentration of tertiary hospitals, research universities, and biotech infrastructure.
Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.
Top comments (0)